Evidence map›Paper›PMID 35821169›Full record

ArticleClinical rheumatology2022

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.

Laura C Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, Atul Deodhar

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Laura C CoatesNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Philip MeaseSwedish Medical Center/Providence St, Joseph Health and University of Washington, Seattle, WA, USA.
Andris KronbergsEli Lilly and Company, Indianapolis, IN, USA.
Cameron HeltEli Lilly and Company, Indianapolis, IN, USA.
David SandovalEli Lilly and Company, Indianapolis, IN, USA.
So Young ParkEli Lilly and Company, Indianapolis, IN, USA.
Bernard CombeUniversity of Montpellier, Montpellier, France.
Peter NashDepartment of Medicine, University of Queensland, Queensland, Brisbane, Australia.
Atul DeodharDivision of Arthritis and Rheumatic Diseases, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Rd, Portland, OR, 97239, USA. deodhara@ohsu.edu.ORCID http://orcid.org/0000-0002-2130-1246
Eli Lilly (United States) · USNuffield Orthopaedic Centre · GBOregon Health & Science University · USProvidence College · USThe University of Queensland · AUUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35821169
PMCPMC9485082
OpenAlexW4285095617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.